• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Association between serum ferritin level and decreased diffusion capacity 3 months after the onset of COVID-19 pneumonia

tetano

Editor, Senior Moderator
PLoS One


. 2023 Feb 16;18(2):e0281249.
doi: 10.1371/journal.pone.0281249. eCollection 2023.
Association between serum ferritin level and decreased diffusion capacity 3 months after the onset of COVID-19 pneumonia


Kyota Shinfuku[SUP] 1 [/SUP], Naoki Takasaka[SUP] 1 [/SUP], Taiki Fukuda[SUP] 2 [/SUP], Kentaro Chida[SUP] 1 [/SUP], Yudai Suzuki[SUP] 1 [/SUP], Shun Shibata[SUP] 1 [/SUP], Ayako Kojima[SUP] 1 [/SUP], Tsukasa Hasegawa[SUP] 1 [/SUP], Masami Yamada[SUP] 1 [/SUP], Yumie Yamanaka[SUP] 1 [/SUP], Yusuke Hosaka[SUP] 1 [/SUP], Aya Seki[SUP] 1 [/SUP], Yoshitaka Seki[SUP] 1 [/SUP], Hiroshi Takeda[SUP] 1 [/SUP], Takeo Ishikawa[SUP] 1 [/SUP], Kazuyoshi Kuwano[SUP] 3 [/SUP]



Affiliations

Abstract

Background: Coronavirus disease 2019 (COVID-19) pneumonia can have prolonged sequelae and lead to respiratory dysfunction, mainly because of impaired diffusion capacity for carbon monoxide (DLCO). The clinical factors associated with DLCO impairment, including blood biochemistry test parameters, remain unclear.
Methods: Patients with COVID-19 pneumonia who underwent inpatient treatment between April 2020 and August 2021 were included in this study. A pulmonary function test was performed 3 months after onset, and the sequelae symptoms were investigated. Clinical factors, including blood test parameters and abnormal chest shadows on computed tomography, of COVID-19 pneumonia associated with DLCO impairment were investigated.
Results: In total, 54 recovered patients participated in this study. Twenty-six patients (48%) and 12 patients (22%) had sequelae symptoms 2 and 3 months after, respectively. The main sequelae symptoms at 3 months were dyspnea and general malaise. Pulmonary function tests showed that 13 patients (24%) had both DLCO <80% predicted value (pred) and DLCO/alveolar volume (VA) <80% pred, and appeared to have DLCO impairment not attributable to an abnormal lung volume. Clinical factors associated with impaired DLCO were investigated in multivariable regression analysis. Ferritin level of >686.5 ng/mL (odds ratio: 11.08, 95% confidence interval [CI]: 1.84-66.59; p = 0.009) was most strongly associated with DLCO impairment.
Conclusions: Decreased DLCO was the most common respiratory function impairment, and ferritin level was a significantly associated clinical factor. Serum ferritin level could be used as a predictor of DLCO impairment in cases of COVID-19 pneumonia.
 
Back
Top Bottom